Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

ID: MRFR/HC/5482-CR 124 Pages Vikita Thakur Last Updated: September 30, 2026
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Research Report By Diagnosis Type (Electromyography, Nerve Conduction Studies, Lumbar Puncture), By Treatment Type (Immunosuppressive Therapy, Intravenous Immunoglobulin, Plasmapheresis, Corticosteroids), By Distribution Channel (Hospitals, Pharmacies, Online Pharmacies, Specialty Clinics), By End User (Hospitals, Research Institutions, Homecare Settings) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)7.3%
2024 Market Size$ 1,995.78 Million
2025 Market Size$ 2,141.47 Million
2035 Market Size$ 4,332.21 Million
Key Players
Bristol Myers Squibb
Sanofi
Teva Pharmaceutical Industries
Novartis
Roche
Pfizer
Opportunities
  • Enhanced Patient Support Programs
  • Innovations in Therapeutic Approaches
  • Growing Demand for Personalized Medicine
  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
    1. 1.1 EXECUTIVE SUMMARY | |
      1. 1.1.1 Market Overview | |
      2. 1.1.2 Key Findings | |
      3. 1.1.3 Market Segmentation | |
      4. 1.1.4 Competitive Landscape | |
      5. 1.1.5 Challenges and Opportunities | |
      6. 1.1.6 Future Outlook 2
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
    1. 2.1 MARKET INTRODUCTION | |
      1. 2.1.1 Definition | |
      2. 2.1.2 Scope of the study | | |
        1. 2.1.2.1 Research Objective | | |
        2. 2.1.2.2 Assumption | | |
        3. 2.1.2.3 Limitations |
    2. 2.2 RESEARCH METHODOLOGY | |
      1. 2.2.1 Overview | |
      2. 2.2.2 Data Mining | |
      3. 2.2.3 Secondary Research | |
      4. 2.2.4 Primary Research | | |
        1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
        2. 2.2.4.2 Breakdown of Primary Respondents | |
      5. 2.2.5 Forecasting Model | |
      6. 2.2.6 Market Size Estimation | | |
        1. 2.2.6.1 Bottom-Up Approach | | |
        2. 2.2.6.2 Top-Down Approach | |
      7. 2.2.7 Data Triangulation | |
      8. 2.2.8 Validation 3
  3. SECTION III: QUALITATIVE ANALYSIS |
    1. 3.1 MARKET DYNAMICS | |
      1. 3.1.1 Overview | |
      2. 3.1.2 Drivers | |
      3. 3.1.3 Restraints | |
      4. 3.1.4 Opportunities |
    2. 3.2 MARKET FACTOR ANALYSIS | |
      1. 3.2.1 Value chain Analysis | |
      2. 3.2.2 Porter's Five Forces Analysis | | |
        1. 3.2.2.1 Bargaining Power of Suppliers | | |
        2. 3.2.2.2 Bargaining Power of Buyers | | |
        3. 3.2.2.3 Threat of New Entrants | | |
        4. 3.2.2.4 Threat of Substitutes | | |
        5. 3.2.2.5 Intensity of Rivalry | |
      3. 3.2.3 COVID-19 Impact Analysis | | |
        1. 3.2.3.1 Market Impact Analysis | | |
        2. 3.2.3.2 Regional Impact | | |
        3. 3.2.3.3 Opportunity and Threat Analysis 4
  4. SECTION IV: QUANTITATIVE ANALYSIS |
    1. 4.1 Healthcare, BY Treatment Type (USD Million) | |
      1. 4.1.1 Immunotherapy | |
      2. 4.1.2 Plasmapheresis | |
      3. 4.1.3 Corticosteroids | |
      4. 4.1.4 Intravenous Immunoglobulin | |
      5. 4.1.5 Physical Therapy |
    2. 4.2 Healthcare, BY Diagnosis Method (USD Million) | |
      1. 4.2.1 Electromyography | |
      2. 4.2.2 Nerve Conduction Studies | |
      3. 4.2.3 Blood Tests | |
      4. 4.2.4 Lumbar Puncture | |
      5. 4.2.5 Clinical Evaluation |
    3. 4.3 Healthcare, BY Patient Demographics (USD Million) | |
      1. 4.3.1 Age Group | |
      2. 4.3.2 Gender | |
      3. 4.3.3 Comorbidities | |
      4. 4.3.4 Socioeconomic Status | |
      5. 4.3.5 Geographic Distribution |
    4. 4.4 Healthcare, BY Disease Severity (USD Million) | |
      1. 4.4.1 Mild | |
      2. 4.4.2 Moderate | |
      3. 4.4.3 Severe | |
      4. 4.4.4 Progressive | |
      5. 4.4.5 Relapsing |
    5. 4.5 Healthcare, BY Region (USD Million) | |
      1. 4.5.1 North America | | |
        1. 4.5.1.1 US | | |
        2. 4.5.1.2 Canada | |
      2. 4.5.2 Europe | | |
        1. 4.5.2.1 Germany | | |
        2. 4.5.2.2 UK | | |
        3. 4.5.2.3 France | | |
        4. 4.5.2.4 Russia | | |
        5. 4.5.2.5 Italy | | |
        6. 4.5.2.6 Spain | | |
        7. 4.5.2.7 Rest of Europe | |
      3. 4.5.3 APAC | | |
        1. 4.5.3.1 China | | |
        2. 4.5.3.2 India | | |
        3. 4.5.3.3 Japan | | |
        4. 4.5.3.4 South Korea | | |
        5. 4.5.3.5 Malaysia | | |
        6. 4.5.3.6 Thailand | | |
        7. 4.5.3.7 Indonesia | | |
        8. 4.5.3.8 Rest of APAC | |
      4. 4.5.4 South America | | |
        1. 4.5.4.1 Brazil | | |
        2. 4.5.4.2 Mexico | | |
        3. 4.5.4.3 Argentina | | |
        4. 4.5.4.4 Rest of South America | |
      5. 4.5.5 MEA | | |
        1. 4.5.5.1 GCC Countries | | |
        2. 4.5.5.2 South Africa | | |
        3. 4.5.5.3 Rest of MEA 5
  5. SECTION V: COMPETITIVE ANALYSIS |
    1. 5.1 Competitive Landscape | |
      1. 5.1.1 Overview | |
      2. 5.1.2 Competitive Analysis | |
      3. 5.1.3 Market share Analysis | |
      4. 5.1.4 Major Growth Strategy in the Healthcare | |
      5. 5.1.5 Competitive Benchmarking | |
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
      7. 5.1.7 Key developments and growth strategies | | |
        1. 5.1.7.1 New Product Launch/Service Deployment | | |
        2. 5.1.7.2 Merger & Acquisitions | | |
        3. 5.1.7.3 Joint Ventures | |
      8. 5.1.8 Major Players Financial Matrix | | |
        1. 5.1.8.1 Sales and Operating Income | | |
        2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
    2. 5.2 Company Profiles | |
      1. 5.2.1 Bristol Myers Squibb (US) | | |
        1. 5.2.1.1 Financial Overview | | |
        2. 5.2.1.2 Products Offered | | |
        3. 5.2.1.3 Key Developments | | |
        4. 5.2.1.4 SWOT Analysis | | |
        5. 5.2.1.5 Key Strategies | |
      2. 5.2.2 Sanofi (FR) | | |
        1. 5.2.2.1 Financial Overview | | |
        2. 5.2.2.2 Products Offered | | |
        3. 5.2.2.3 Key Developments | | |
        4. 5.2.2.4 SWOT Analysis | | |
        5. 5.2.2.5 Key Strategies | |
      3. 5.2.3 Teva Pharmaceutical Industries (IL) | | |
        1. 5.2.3.1 Financial Overview | | |
        2. 5.2.3.2 Products Offered | | |
        3. 5.2.3.3 Key Developments | | |
        4. 5.2.3.4 SWOT Analysis | | |
        5. 5.2.3.5 Key Strategies | |
      4. 5.2.4 Novartis (CH) | | |
        1. 5.2.4.1 Financial Overview | | |
        2. 5.2.4.2 Products Offered | | |
        3. 5.2.4.3 Key Developments | | |
        4. 5.2.4.4 SWOT Analysis | | |
        5. 5.2.4.5 Key Strategies | |
      5. 5.2.5 Roche (CH) | | |
        1. 5.2.5.1 Financial Overview | | |
        2. 5.2.5.2 Products Offered | | |
        3. 5.2.5.3 Key Developments | | |
        4. 5.2.5.4 SWOT Analysis | | |
        5. 5.2.5.5 Key Strategies | |
      6. 5.2.6 Pfizer (US) | | |
        1. 5.2.6.1 Financial Overview | | |
        2. 5.2.6.2 Products Offered | | |
        3. 5.2.6.3 Key Developments | | |
        4. 5.2.6.4 SWOT Analysis | | |
        5. 5.2.6.5 Key Strategies | |
      7. 5.2.7 AstraZeneca (GB) | | |
        1. 5.2.7.1 Financial Overview | | |
        2. 5.2.7.2 Products Offered | | |
        3. 5.2.7.3 Key Developments | | |
        4. 5.2.7.4 SWOT Analysis | | |
        5. 5.2.7.5 Key Strategies | |
      8. 5.2.8 Eisai Co., Ltd. (JP) | | |
        1. 5.2.8.1 Financial Overview | | |
        2. 5.2.8.2 Products Offered | | |
        3. 5.2.8.3 Key Developments | | |
        4. 5.2.8.4 SWOT Analysis | | |
        5. 5.2.8.5 Key Strategies | |
      9. 5.2.9 Mylan N.V. (US) | | |
        1. 5.2.9.1 Financial Overview | | |
        2. 5.2.9.2 Products Offered | | |
        3. 5.2.9.3 Key Developments | | |
        4. 5.2.9.4 SWOT Analysis | | |
        5. 5.2.9.5 Key Strategies |
    3. 5.3 Appendix | |
      1. 5.3.1 References | |
      2. 5.3.2 Related Reports 6 LIST OF FIGURES |
    4. 6.1 MARKET SYNOPSIS |
    5. 6.2 NORTH AMERICA MARKET ANALYSIS |
    6. 6.3 US MARKET ANALYSIS BY TREATMENT TYPE |
    7. 6.4 US MARKET ANALYSIS BY DIAGNOSIS METHOD |
    8. 6.5 US MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    9. 6.6 US MARKET ANALYSIS BY DISEASE SEVERITY |
    10. 6.7 CANADA MARKET ANALYSIS BY TREATMENT TYPE |
    11. 6.8 CANADA MARKET ANALYSIS BY DIAGNOSIS METHOD |
    12. 6.9 CANADA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    13. 6.10 CANADA MARKET ANALYSIS BY DISEASE SEVERITY |
    14. 6.11 EUROPE MARKET ANALYSIS |
    15. 6.12 GERMANY MARKET ANALYSIS BY TREATMENT TYPE |
    16. 6.13 GERMANY MARKET ANALYSIS BY DIAGNOSIS METHOD |
    17. 6.14 GERMANY MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    18. 6.15 GERMANY MARKET ANALYSIS BY DISEASE SEVERITY |
    19. 6.16 UK MARKET ANALYSIS BY TREATMENT TYPE |
    20. 6.17 UK MARKET ANALYSIS BY DIAGNOSIS METHOD |
    21. 6.18 UK MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    22. 6.19 UK MARKET ANALYSIS BY DISEASE SEVERITY |
    23. 6.20 FRANCE MARKET ANALYSIS BY TREATMENT TYPE |
    24. 6.21 FRANCE MARKET ANALYSIS BY DIAGNOSIS METHOD |
    25. 6.22 FRANCE MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    26. 6.23 FRANCE MARKET ANALYSIS BY DISEASE SEVERITY |
    27. 6.24 RUSSIA MARKET ANALYSIS BY TREATMENT TYPE |
    28. 6.25 RUSSIA MARKET ANALYSIS BY DIAGNOSIS METHOD |
    29. 6.26 RUSSIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    30. 6.27 RUSSIA MARKET ANALYSIS BY DISEASE SEVERITY |
    31. 6.28 ITALY MARKET ANALYSIS BY TREATMENT TYPE |
    32. 6.29 ITALY MARKET ANALYSIS BY DIAGNOSIS METHOD |
    33. 6.30 ITALY MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    34. 6.31 ITALY MARKET ANALYSIS BY DISEASE SEVERITY |
    35. 6.32 SPAIN MARKET ANALYSIS BY TREATMENT TYPE |
    36. 6.33 SPAIN MARKET ANALYSIS BY DIAGNOSIS METHOD |
    37. 6.34 SPAIN MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    38. 6.35 SPAIN MARKET ANALYSIS BY DISEASE SEVERITY |
    39. 6.36 REST OF EUROPE MARKET ANALYSIS BY TREATMENT TYPE |
    40. 6.37 REST OF EUROPE MARKET ANALYSIS BY DIAGNOSIS METHOD |
    41. 6.38 REST OF EUROPE MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    42. 6.39 REST OF EUROPE MARKET ANALYSIS BY DISEASE SEVERITY |
    43. 6.40 APAC MARKET ANALYSIS |
    44. 6.41 CHINA MARKET ANALYSIS BY TREATMENT TYPE |
    45. 6.42 CHINA MARKET ANALYSIS BY DIAGNOSIS METHOD |
    46. 6.43 CHINA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    47. 6.44 CHINA MARKET ANALYSIS BY DISEASE SEVERITY |
    48. 6.45 INDIA MARKET ANALYSIS BY TREATMENT TYPE |
    49. 6.46 INDIA MARKET ANALYSIS BY DIAGNOSIS METHOD |
    50. 6.47 INDIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    51. 6.48 INDIA MARKET ANALYSIS BY DISEASE SEVERITY |
    52. 6.49 JAPAN MARKET ANALYSIS BY TREATMENT TYPE |
    53. 6.50 JAPAN MARKET ANALYSIS BY DIAGNOSIS METHOD |
    54. 6.51 JAPAN MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    55. 6.52 JAPAN MARKET ANALYSIS BY DISEASE SEVERITY |
    56. 6.53 SOUTH KOREA MARKET ANALYSIS BY TREATMENT TYPE |
    57. 6.54 SOUTH KOREA MARKET ANALYSIS BY DIAGNOSIS METHOD |
    58. 6.55 SOUTH KOREA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    59. 6.56 SOUTH KOREA MARKET ANALYSIS BY DISEASE SEVERITY |
    60. 6.57 MALAYSIA MARKET ANALYSIS BY TREATMENT TYPE |
    61. 6.58 MALAYSIA MARKET ANALYSIS BY DIAGNOSIS METHOD |
    62. 6.59 MALAYSIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    63. 6.60 MALAYSIA MARKET ANALYSIS BY DISEASE SEVERITY |
    64. 6.61 THAILAND MARKET ANALYSIS BY TREATMENT TYPE |
    65. 6.62 THAILAND MARKET ANALYSIS BY DIAGNOSIS METHOD |
    66. 6.63 THAILAND MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    67. 6.64 THAILAND MARKET ANALYSIS BY DISEASE SEVERITY |
    68. 6.65 INDONESIA MARKET ANALYSIS BY TREATMENT TYPE |
    69. 6.66 INDONESIA MARKET ANALYSIS BY DIAGNOSIS METHOD |
    70. 6.67 INDONESIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    71. 6.68 INDONESIA MARKET ANALYSIS BY DISEASE SEVERITY |
    72. 6.69 REST OF APAC MARKET ANALYSIS BY TREATMENT TYPE |
    73. 6.70 REST OF APAC MARKET ANALYSIS BY DIAGNOSIS METHOD |
    74. 6.71 REST OF APAC MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    75. 6.72 REST OF APAC MARKET ANALYSIS BY DISEASE SEVERITY |
    76. 6.73 SOUTH AMERICA MARKET ANALYSIS |
    77. 6.74 BRAZIL MARKET ANALYSIS BY TREATMENT TYPE |
    78. 6.75 BRAZIL MARKET ANALYSIS BY DIAGNOSIS METHOD |
    79. 6.76 BRAZIL MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    80. 6.77 BRAZIL MARKET ANALYSIS BY DISEASE SEVERITY |
    81. 6.78 MEXICO MARKET ANALYSIS BY TREATMENT TYPE |
    82. 6.79 MEXICO MARKET ANALYSIS BY DIAGNOSIS METHOD |
    83. 6.80 MEXICO MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    84. 6.81 MEXICO MARKET ANALYSIS BY DISEASE SEVERITY |
    85. 6.82 ARGENTINA MARKET ANALYSIS BY TREATMENT TYPE |
    86. 6.83 ARGENTINA MARKET ANALYSIS BY DIAGNOSIS METHOD |
    87. 6.84 ARGENTINA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    88. 6.85 ARGENTINA MARKET ANALYSIS BY DISEASE SEVERITY |
    89. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT TYPE |
    90. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY DIAGNOSIS METHOD |
    91. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    92. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISEASE SEVERITY |
    93. 6.90 MEA MARKET ANALYSIS |
    94. 6.91 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT TYPE |
    95. 6.92 GCC COUNTRIES MARKET ANALYSIS BY DIAGNOSIS METHOD |
    96. 6.93 GCC COUNTRIES MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    97. 6.94 GCC COUNTRIES MARKET ANALYSIS BY DISEASE SEVERITY |
    98. 6.95 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT TYPE |
    99. 6.96 SOUTH AFRICA MARKET ANALYSIS BY DIAGNOSIS METHOD |
    100. 6.97 SOUTH AFRICA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    101. 6.98 SOUTH AFRICA MARKET ANALYSIS BY DISEASE SEVERITY |
    102. 6.99 REST OF MEA MARKET ANALYSIS BY TREATMENT TYPE |
    103. 6.100 REST OF MEA MARKET ANALYSIS BY DIAGNOSIS METHOD |
    104. 6.101 REST OF MEA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    105. 6.102 REST OF MEA MARKET ANALYSIS BY DISEASE SEVERITY |
    106. 6.103 KEY BUYING CRITERIA OF HEALTHCARE |
    107. 6.104 RESEARCH PROCESS OF MRFR |
    108. 6.105 DRO ANALYSIS OF HEALTHCARE |
    109. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
    110. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
    111. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE |
    112. 6.109 HEALTHCARE, BY TREATMENT TYPE, 2024 (% SHARE) |
    113. 6.110 HEALTHCARE, BY TREATMENT TYPE, 2024 TO 2035 (USD Million) |
    114. 6.111 HEALTHCARE, BY DIAGNOSIS METHOD, 2024 (% SHARE) |
    115. 6.112 HEALTHCARE, BY DIAGNOSIS METHOD, 2024 TO 2035 (USD Million) |
    116. 6.113 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 (% SHARE) |
    117. 6.114 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 TO 2035 (USD Million) |
    118. 6.115 HEALTHCARE, BY DISEASE SEVERITY, 2024 (% SHARE) |
    119. 6.116 HEALTHCARE, BY DISEASE SEVERITY, 2024 TO 2035 (USD Million) |
    120. 6.117 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
    121. 7.1 LIST OF ASSUMPTIONS | |
      1. 7.1.1 |
    122. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.2.1 BY TREATMENT TYPE, 2026-2035 (USD Million) | |
      2. 7.2.2 BY DIAGNOSIS METHOD, 2026-2035 (USD Million) | |
      3. 7.2.3 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million) | |
      4. 7.2.4 BY DISEASE SEVERITY, 2026-2035 (USD Million) |
    123. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.3.1 BY TREATMENT TYPE, 2026-2035 (USD Million) | |
      2. 7.3.2 BY DIAGNOSIS METHOD, 2026-2035 (USD Million) | |
      3. 7.3.3 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million) | |
      4. 7.3.4 BY DISEASE SEVERITY, 2026-2035 (USD Million) |
    124. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.4.1 BY TREATMENT TYPE, 2026-2035 (USD Million) | |
      2. 7.4.2 BY DIAGNOSIS METHOD, 2026-2035 (USD Million) | |
      3. 7.4.3 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million) | |
      4. 7.4.4 BY DISEASE SEVERITY, 2026-2035 (USD Million) |
    125. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.5.1 BY TREATMENT TYPE, 2026-2035 (USD Million) | |
      2. 7.5.2 BY DIAGNOSIS METHOD, 2026-2035 (USD Million) | |
      3. 7.5.3 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million) | |
      4. 7.5.4 BY DISEASE SEVERITY, 2026-2035 (USD Million) |
    126. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.6.1 BY TREATMENT TYPE, 2026-2035 (USD Million) | |
      2. 7.6.2 BY DIAGNOSIS METHOD, 2026-2035 (USD Million) | |
      3. 7.6.3 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million) | |
      4. 7.6.4 BY DISEASE SEVERITY, 2026-2035 (USD Million) |
    127. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.7.1 BY TREATMENT TYPE, 2026-2035 (USD Million) | |
      2. 7.7.2 BY DIAGNOSIS METHOD, 2026-2035 (USD Million) | |
      3. 7.7.3 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million) | |
      4. 7.7.4 BY DISEASE SEVERITY, 2026-2035 (USD Million) |
    128. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.8.1 BY TREATMENT TYPE, 2026-2035 (USD Million) | |
      2. 7.8.2 BY DIAGNOSIS METHOD, 2026-2035 (USD Million) | |
      3. 7.8.3 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million) | |
      4. 7.8.4 BY DISEASE SEVERITY, 2026-2035 (USD Million) |
    129. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.9.1 BY TREATMENT TYPE, 2026-2035 (USD Million) | |
      2. 7.9.2 BY DIAGNOSIS METHOD, 2026-2035 (USD Million) | |
      3. 7.9.3 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million) | |
      4. 7.9.4 BY DISEASE SEVERITY, 2026-2035 (USD Million) |
    130. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.10.1 BY TREATMENT TYPE, 2026-2035 (USD Million) | |
      2. 7.10.2 BY DIAGNOSIS METHOD, 2026-2035 (USD Million) | |
      3. 7.10.3 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million) | |
      4. 7.10.4 BY DISEASE SEVERITY, 2026-2035 (USD Million) |
    131. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.11.1 BY TREATMENT TYPE, 2026-2035 (USD Million) | |
      2. 7.11.2 BY DIAGNOSIS METHOD, 2026-2035 (USD Million) | |
      3. 7.11.3 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million) | |
      4. 7.11.4 BY DISEASE SEVERITY, 2026-2035 (USD Million) |
    132. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.12.1 BY TREATMENT TYPE, 2026-2035 (USD Million) | |
      2. 7.12.2 BY DIAGNOSIS METHOD, 2026-2035 (USD Million) | |
      3. 7.12.3 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million) | |
      4. 7.12.4 BY DISEASE SEVERITY, 2026-2035 (USD Million) |
    133. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.13.1 BY TREATMENT TYPE, 2026-2035 (USD Million) | |
      2. 7.13.2 BY DIAGNOSIS METHOD, 2026-2035 (USD Million) | |
      3. 7.13.3 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million) | |
      4. 7.13.4 BY DISEASE SEVERITY, 2026-2035 (USD Million) |
    134. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.14.1 BY TREATMENT TYPE, 2026-2035 (USD Million) | |
      2. 7.14.2 BY DIAGNOSIS METHOD, 2026-2035 (USD Million) | |
      3. 7.14.3 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million) | |
      4. 7.14.4 BY DISEASE SEVERITY, 2026-2035 (USD Million) |
    135. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.15.1 BY TREATMENT TYPE, 2026-2035 (USD Million) | |
      2. 7.15.2 BY DIAGNOSIS METHOD, 2026-2035 (USD Million) | |
      3. 7.15.3 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million) | |
      4. 7.15.4 BY DISEASE SEVERITY, 2026-2035 (USD Million) |
    136. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.16.1 BY TREATMENT TYPE, 2026-2035 (USD Million) | |
      2. 7.16.2 BY DIAGNOSIS METHOD, 2026-2035 (USD Million) | |
      3. 7.16.3 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million) | |
      4. 7.16.4 BY DISEASE SEVERITY, 2026-2035 (USD Million) |
    137. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.17.1 BY TREATMENT TYPE, 2026-2035 (USD Million) | |
      2. 7.17.2 BY DIAGNOSIS METHOD, 2026-2035 (USD Million) | |
      3. 7.17.3 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million) | |
      4. 7.17.4 BY DISEASE SEVERITY, 2026-2035 (USD Million) |
    138. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.18.1 BY TREATMENT TYPE, 2026-2035 (USD Million) | |
      2. 7.18.2 BY DIAGNOSIS METHOD, 2026-2035 (USD Million) | |
      3. 7.18.3 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million) | |
      4. 7.18.4 BY DISEASE SEVERITY, 2026-2035 (USD Million) |
    139. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.19.1 BY TREATMENT TYPE, 2026-2035 (USD Million) | |
      2. 7.19.2 BY DIAGNOSIS METHOD, 2026-2035 (USD Million) | |
      3. 7.19.3 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million) | |
      4. 7.19.4 BY DISEASE SEVERITY, 2026-2035 (USD Million) |
    140. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.20.1 BY TREATMENT TYPE, 2026-2035 (USD Million) | |
      2. 7.20.2 BY DIAGNOSIS METHOD, 2026-2035 (USD Million) | |
      3. 7.20.3 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million) | |
      4. 7.20.4 BY DISEASE SEVERITY, 2026-2035 (USD Million) |
    141. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.21.1 BY TREATMENT TYPE, 2026-2035 (USD Million) | |
      2. 7.21.2 BY DIAGNOSIS METHOD, 2026-2035 (USD Million) | |
      3. 7.21.3 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million) | |
      4. 7.21.4 BY DISEASE SEVERITY, 2026-2035 (USD Million) |
    142. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.22.1 BY TREATMENT TYPE, 2026-2035 (USD Million) | |
      2. 7.22.2 BY DIAGNOSIS METHOD, 2026-2035 (USD Million) | |
      3. 7.22.3 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million) | |
      4. 7.22.4 BY DISEASE SEVERITY, 2026-2035 (USD Million) |
    143. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.23.1 BY TREATMENT TYPE, 2026-2035 (USD Million) | |
      2. 7.23.2 BY DIAGNOSIS METHOD, 2026-2035 (USD Million) | |
      3. 7.23.3 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million) | |
      4. 7.23.4 BY DISEASE SEVERITY, 2026-2035 (USD Million) |
    144. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.24.1 BY TREATMENT TYPE, 2026-2035 (USD Million) | |
      2. 7.24.2 BY DIAGNOSIS METHOD, 2026-2035 (USD Million) | |
      3. 7.24.3 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million) | |
      4. 7.24.4 BY DISEASE SEVERITY, 2026-2035 (USD Million) |
    145. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.25.1 BY TREATMENT TYPE, 2026-2035 (USD Million) | |
      2. 7.25.2 BY DIAGNOSIS METHOD, 2026-2035 (USD Million) | |
      3. 7.25.3 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million) | |
      4. 7.25.4 BY DISEASE SEVERITY, 2026-2035 (USD Million) |
    146. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.26.1 BY TREATMENT TYPE, 2026-2035 (USD Million) | |
      2. 7.26.2 BY DIAGNOSIS METHOD, 2026-2035 (USD Million) | |
      3. 7.26.3 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million) | |
      4. 7.26.4 BY DISEASE SEVERITY, 2026-2035 (USD Million) |
    147. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.27.1 BY TREATMENT TYPE, 2026-2035 (USD Million) | |
      2. 7.27.2 BY DIAGNOSIS METHOD, 2026-2035 (USD Million) | |
      3. 7.27.3 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million) | |
      4. 7.27.4 BY DISEASE SEVERITY, 2026-2035 (USD Million) |
    148. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.28.1 BY TREATMENT TYPE, 2026-2035 (USD Million) | |
      2. 7.28.2 BY DIAGNOSIS METHOD, 2026-2035 (USD Million) | |
      3. 7.28.3 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million) | |
      4. 7.28.4 BY DISEASE SEVERITY, 2026-2035 (USD Million) |
    149. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.29.1 BY TREATMENT TYPE, 2026-2035 (USD Million) | |
      2. 7.29.2 BY DIAGNOSIS METHOD, 2026-2035 (USD Million) | |
      3. 7.29.3 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million) | |
      4. 7.29.4 BY DISEASE SEVERITY, 2026-2035 (USD Million) |
    150. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.30.1 BY TREATMENT TYPE, 2026-2035 (USD Million) | |
      2. 7.30.2 BY DIAGNOSIS METHOD, 2026-2035 (USD Million) | |
      3. 7.30.3 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million) | |
      4. 7.30.4 BY DISEASE SEVERITY, 2026-2035 (USD Million) |
    151. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
      1. 7.31.1 |
    152. 7.32 ACQUISITION/PARTNERSHIP | |

Chronic Inflammatory Demyelinating Polyneuropathy Market Segmentation

Chronic Inflammatory Demyelinating Polyneuropathy Market By Treatment Type (USD Million, 2022-2035)

  • Immunotherapy
  • Plasmapheresis
  • Corticosteroids
  • Intravenous Immunoglobulin
  • Physical Therapy

Chronic Inflammatory Demyelinating Polyneuropathy Market By Diagnosis Method (USD Million, 2022-2035)

  • Electromyography
  • Nerve Conduction Studies
  • Blood Tests
  • Lumbar Puncture
  • Clinical Evaluation

Chronic Inflammatory Demyelinating Polyneuropathy Market By Patient Demographics (USD Million, 2022-2035)

  • Age Group
  • Gender
  • Comorbidities
  • Socioeconomic Status
  • Geographic Distribution

Chronic Inflammatory Demyelinating Polyneuropathy Market By Disease Severity (USD Million, 2022-2035)

  • Mild
  • Moderate
  • Severe
  • Progressive
  • Relapsing
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.